Michèle Beau-Faller, MD, PhD, on NSCLC: Biomarker Findings From the French Cooperative Thoracic Intergroup
2017 ESMO CongressMichèle Beau-Faller, MD, PhD, of the Hôpital de Hautepierre & Institut Régional du Cancer, discusses study results on ultrasensitive detection of EGFR T790M mutation by droplet digital PCR in TKI naïve non–small cell lung cancer harboring EGFR mutation (Abstract 85PD).
Related Videos
Jaafar Bennouna, MD, on Colorectal Cancer: Clinical Trial Findings on Targeted Treatments and Chemotherapy
Jaafar Bennouna, MD, of the University of Nantes, discusses findings from a phase II French study of bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab p...
Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials
Sandro Pignata, MD, PhD, of the Istituto Nazionale dei Tumori, summarizes findings from the ICON8 study on dose-dense chemotherapy integration in first-line epithelial ovarian/fall...
Sibylle Loibl, MD, PhD, on Metastatic Breast Cancer: Expert Perspective on CDK4 Inhibitors
Sibylle Loibl, MD, PhD, of the German Breast Group, summarizes a session she chaired in which the rationale to target CDK4, data on efficacy of the inhibitors, and triple combinati...
Manuel Hidalgo, MD, PhD, on Biliary Tract Cancer: Results From the PRODIGY 12-ACCORD 18 Trial
Manuel Hidalgo, MD, PhD, of Harvard Medical School, discusses updated phase III findings on relapse-free survival and first overall survival results in adjuvant GEMOX (gemcitabine ...
Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negati...
